Payment overview · 2025
General Payments
$345.41
15 reported records · 8 companies
Healthcare provider profile · identity verified
Whitni Michael Richard, DO
Allopathic & Osteopathic Physicians|Family Medicine · ENTERPRISE, AL · NPI 1609385293
Verified facts
What the public records show
CMS Open Payments records show Whitni Michael Richard, DO received $345.41 in general payments during 2025 across 15 reported records.
Medtronic, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$84.16 | 24.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.48 | 19.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.37 | 19.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.81 | 9.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.66 | 9.7% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.14 | 7.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 5.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.94 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.56 | 14 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $84.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.40 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 207 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 183 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 125 | 41 |
| Losartan Potassium | Losartan Potassium | 122 | 37 |
| Omeprazole | Omeprazole | 117 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 33 |
| Lisinopril | Lisinopril | 90 | 31 |
| Metformin Hcl | Metformin Hcl | 87 | 29 |
| Buspirone Hcl | Buspirone Hcl | 86 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 23 |
| Meloxicam | Meloxicam | 72 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 25 |
| Ibuprofen | Ibuprofen | 69 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 25 |
| Furosemide | Furosemide | 62 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 23 |
| Potassium Chloride | Potassium Chloride | 58 | 16 |
| Simvastatin | Simvastatin | 58 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 12 |
| Donepezil Hcl | Donepezil Hcl | 55 | 14 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Tramadol Hcl | Tramadol Hcl | 51 | 13 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 20 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 18 |
| Famotidine | Famotidine | 42 | 13 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Glipizide | Glipizide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enstilar | Calcipotriene/Betamethasone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $345.41 · 15 records | Medtronic, Inc. | AIRSUPRA, AREXVY, Azstarys, BEXSERO, EVENITY, FARXIGA, JARDIANCE, MINIMED 780G, REPATHA, SHINGRIX, TRELEGY ELLIPTA, Tymlos, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error